Sermorelin on TikTok: separating the GHRH hype from real data

What did @pepkitapp actually say?

The creator describes sermorelin as "a synthetic 29 amino acid peptide that mimics the first segment of endogenous growth hormone-releasing hormone." They report a community dose range of 100 to 300 micrograms once daily, subcutaneous injection 30 to 60 minutes before bed in a fasted state. Cycle length they give is "12 to 26 weeks on with four to eight weeks off," which they acknowledge is one of the longer cycles in this category. They also mention an optional five-days-on, two-days-off schedule some users prefer. They credit FDA prescribing information, clinical literature, and community forums as their sources, which is an unusually transparent attribution for a peptide TikTok.

The framing is descriptive, not prescriptive. They are not telling anyone to take this compound. That distinction matters legally and practically, and it's worth noting before tearing into the specifics.

Does the science back this up?

Mostly, yes, with some important gaps. Sermorelin is not a fringe compound. It was FDA-approved under the brand name Geref for treating growth hormone deficiency in children, and it has a legitimate clinical research record. The mechanism is accurate: sermorelin is the 1-29 amino acid fragment of endogenous GHRH, and it stimulates pituitary GH release rather than replacing GH directly.

The bedtime, fasted timing recommendation has real physiological logic behind it. Growth hormone is released in pulses, with the largest pulse occurring during slow-wave sleep. Administering a GHRH analog before sleep takes advantage of this natural rhythm. Walker et al. (1990, Journal of Clinical Endocrinology and Metabolism) demonstrated that GHRH administration augmented nocturnal GH secretion in healthy adults.

The dose range cited, 100 to 300 micrograms, overlaps with ranges used in published clinical trials. Vittone et al. (1997, Metabolism) used 2 mcg per kilogram subcutaneously twice daily in older adults, which for a typical adult puts the single dose in a comparable neighborhood. However, clinical dosing was often weight-based and administered twice daily, which differs from the flat once-daily community protocol described here.

The cycle length of 12 to 26 weeks is longer than most clinical trials ran, and there is limited published data on what happens to pituitary receptor sensitivity over extended community-style cycling. This is a genuine gap, not a scare tactic.

What did they get wrong (or right)?

The molecular description is accurate. The timing rationale is sound. The source attribution is better than average for this content category. Credit where it is due.

The errors are mostly errors of omission rather than commission. Sermorelin's FDA approval was withdrawn in 2008 when the manufacturer discontinued the product, not because of safety concerns. The creator mentions it has "prior FDA approval history," which is technically true but could leave viewers thinking it has a cleaner regulatory status than it does. Compounded sermorelin, which is what most people accessing it today are using, is a different regulatory animal entirely and carries different quality-control considerations.

The "five days on, two days off" schedule is presented as a community observation, and that framing is fair. There is no published clinical trial testing this specific schedule. It is not wrong to report it, but the lack of evidence for it versus continuous dosing should be explicit.

One thing the creator does not address is the pituitary dependence issue. Unlike exogenous HGH, sermorelin requires a functioning pituitary to work. In patients with pituitary dysfunction, it simply will not produce the expected effect. That is a clinically relevant omission for a general audience.

What should you actually know?

Sermorelin has more human data behind it than most peptides discussed in this category. That is a real advantage. The clinical literature includes trials in children with GH deficiency and in older adults being studied for age-related GH decline. It is not a completely uncharted compound.

But the gap between the controlled clinical trial setting and community self-administration is wide. In trials, patients were monitored with IGF-1 measurements, assessed for adverse effects including injection site reactions, edema, and changes in glucose metabolism, and doses were adjusted. Self-administered sermorelin without that monitoring removes the feedback loop that makes clinical use reasonably safe.

Sermorelin also cannot be purchased legally in the United States without a prescription. Compounded versions are available through some telehealth providers prescribing it off-label, but the FDA has raised concerns about compounded peptides more broadly. If someone is genuinely interested in GHRH-based therapy, the conversation starts with a licensed provider who can order baseline labs, not a TikTok video, regardless of how accurate that video happens to be.

The creator includes the disclaimer "not medical advice, consult a healthcare provider." That is the right call. The content itself is more responsible than most in this space, which sets a low bar, but still counts for something.